Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Somatostatinoma × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 119 Neoplasm Metastasis 20 Neoplasms 16 Sarcoma 10 Ovarian Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Pancreatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Endometrial Neoplasms 6 Colorectal Neoplasms 6 Prostatic Neoplasms 5 Melanoma 5 Lymphoma, Non-Hodgkin 5 Head and Neck Neoplasms 5 Sarcoma, Ewing 4 Recurrence 4 Multiple Myeloma 4 Medulloblastoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Breast Diseases 4 Triple Negative Breast Neoplasms 3 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Osteosarcoma 3 Neuroblastoma 3 Liposarcoma 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3

Interventions

Octreotide 4 Leucovorin 4 Capecitabine 4 Temozolomide 3 Fluorouracil 3 Everolimus 3 vatalanib 2 Trastuzumab 2 Sunitinib 2 Oxaliplatin 2 Magnetic Resonance Spectroscopy 2 Cisplatin 2 Bortezomib 2 Bevacizumab 2 veliparib 1 tipifarnib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 pentetreotide 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 cixutumumab 1 batifiban 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02806648 2018-01-23

PALBONET

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡